With coronavirus mutations splintering like shrapnel, some COVID-19 treatments are facing decreased efficacy — but the decision to pull a therapy off the market can get murky, The Atlantic reported Oct. 29.
Read the full post on Becker's Hospital Review - Healthcare News
